Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs

BACKGROUND: The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contribute to the survival and development of resistance in response to therapy. Thi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Breast Cancer Res
Päätekijät: Reddy, Tejaswini P., Choi, Dong S., Anselme, Ann C., Qian, Wei, Chen, Wen, Lantto, Johan, Horak, Ivan D., Kragh, Michael, Chang, Jenny C., Rosato, Roberto R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7227035/
https://ncbi.nlm.nih.gov/pubmed/32414394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01280-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia